

**SUPPLEMENTARY MATERIAL #4****IMPACT OF STATINS ON FIB-4 PREDICTIONS: BASELINE****CHARACTERISTIC OF PATIENTS WITH HYDROPHILIC AND****LIPOPHILIC STATIN**

Table: Baseline characteristic of patients with hydrophilic and lipophilic statins

Variable(unit)	Patients on Hydrophilic Statin	Patients on Lipophilic Statin
<b>Demographic data</b>		
Number of patients (n)	85	44
Age (Year)	50(45-57)	53 (49- 59)
Sex, n(%Male)	61 (71.76%)	32 (72.70%)
BMI (Kg/ M <sup>2</sup> )	31.97 (28.12-34.82)	33.37 (30.41-36.33)
<b>Liver Function Test</b>		
AST (U/L)	39 (31 -52)	32 (27-48)
ALT (U/L)	61(42 -64)	56 (44-76)
Total Bilirubin (umol/L)	11 (9-15)	11(8-15)
Albumin (g/L)	45 (44-47)	45 (43-46)
GGT (U/L)	67 (36-125)	56 (38-153)
Platelets (10 <sup>9</sup> /L)	218 (188 -262)	232 (195-256)
<b>Diabetes profile</b>		
HB <sup>A1C</sup> (%)	5.9 (5.6-6.7)	6.4 (5.8-7.2)
Fasting Plasma Glucose (mmol/L)	6.1 (5.3-6.8)	6.6 (5.5-8.6)
<b>Diabetic classification</b>		
Diabetes (n)	35 (41.2%)	26(59.10%)
Prediabetes (n)	34 (40.0%)	10(22.70%)
Normal (n)	16 (18.8%)	8(18.20%)
<b>Lipid profile</b>		
Total Cholesterol (mmol/L)	4.05 (3.58-4.66)	4.03 (3.42-4.73)
HDL (mmol/L)	1.15 (0.95-1.32)	1.09 (0.91-1.33)
LDL (mmol/L)	2.02 (1.64-2.48)	1.95 (1.65-2.66)
Non-HDL Cholesterol (mmol/L)	2.84 (2.38-3.41)	2.79 (2.28-3.51)
<b>Non-Invasive Tests</b>		
AST/ALT	0.62 (0.53-0.80)	0.63 (0.55-0.77)
AST/VALT	4.9 (4.10-5.83)	4.21 (3.91-6.06)
FIB4	1.15 (0.91-1.51)	1.11 (0.78-1.50)
NFS	-1.44 (-2.24 -0.66)	-1.13 (-1.88 -0.25)
HEPAMET	0.10 (0.04-0.21)	0.10 (0.04-0.18)
VCTE (kPa)	5.90 (4.80-8.10)	6.15 (4.53-7.75)